[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341335-105":59,"doc-detail-341335-en":135},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":128,"head_meta":130,"extra_data":132,"updated_unix":134},105,"en","a-comprehensive-pan-cancer-analysis-reveals-cyclin-dependent-kinase-inhibitor-2a-gene-as-a-potential-diagnostic-and-prognostic-biomarker-in-colon-adenocarcinoma","A Comprehensive Pan-Cancer Analysis Reveals Cyclin-Dependent Kinase Inhibitor 2A Gene as a Potential Diagnostic and Prognostic Biomarker in Colon Adenocarcinoma","","A comprehensive pan-cancer bioinformatic study evaluates cyclin-dependent kinase inhibitor 2A (CDKN2A) as a diagnostic and prognostic biomarker, emphasizing colon adenocarcinoma (COAD). Gene expression profiling across 32 cancer types using TIMER 2.0, GEPIA, and UALCAN links CDKN2A upregulation with pathological stage differences and poorer patient outcomes. Genetic alterations are examined via cBioPortal and validated using a public GEO cohort, with immune infiltration associations highlighted for COAD.",{"@graph":69,"@context":127},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-comprehensive-pan-cancer-analysis-reveals-cyclin-dependent-kinase-inhibitor-2a-gene-as-a-potential-diagnostic-and-prognostic-biomarker-in-colon-adenocarcinoma/341335/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-comprehensive-pan-cancer-analysis-reveals-cyclin-dependent-kinase-inhibitor-2a-gene-as-a-potential-diagnostic-and-prognostic-biomarker-in-colon-adenocarcinoma/341335.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119,123],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main goal of the study regarding CDKN2A?","Question",{"text":113,"@type":114},"To assess whether CDKN2A can function as a diagnostic and prognostic biomarker across multiple cancer types, with primary focus on colon adenocarcinoma (COAD).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which datasets and bioinformatic tools were used for expression and immune analysis?",{"text":118,"@type":114},"TIMER 2.0, GEPIA, and UALCAN were used for gene expression profiling, while TIMER 2.0 also supports tumor-infiltrating immune cell analysis based on TCGA RNA-seq samples.",{"name":120,"@type":111,"acceptedAnswer":121},"What key findings support CDKN2A’s biomarker potential in COAD?",{"text":122,"@type":114},"CDKN2A shows significant upregulation in COAD, stage-associated differences, and an association with poor survival, along with links between higher expression and immune cell infiltration (e.g., CD4+ T cells, macrophages, neutrophils).",{"name":124,"@type":111,"acceptedAnswer":125},"How were genetic alterations and validation performed?",{"text":126,"@type":114},"Genetic alteration patterns were analyzed using the cBioPortal across multiple pancancer studies, and results were concluded with validation using a public cohort from Gene Expression Omnibus (GEO).","https://schema.org",{"og:url":83,"og:type":129,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":131,"canonical":83},"index,follow",{"doc_id":133,"site_id":62},341335,1790184152,{"code":4,"msg":5,"data":136},{"doc_id":133,"user_id":137,"nickname":92,"user_avatar":138,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":144,"language":145,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":67,"update_tm":149,"read_time":150,"preview_page_count":19,"preview_urls":151},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Open Access Original  \nArticle DOI: 10.7759/cureus.60586  \nReview began 05/07/2024  \nReview ended 05/10/2024  \nPublished 05/19/2024  \n© Copyright 2024  \nSalem et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nA Comprehensive Pan-Cancer Analysis Reveals Cyclin-Dependent Kinase Inhibitor 2A Gene as a Potential Diagnostic and Prognostic Biomarker in Colon Adenocarcinoma  \nAhmed Salem 1, Sanaa Ahmed 2, Maha Khalfallah 3 , Nema Hamadan 4, Walaa ElShikh 5, Mohamed Alfaki 6  \n1. Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, CZE 2. Pharmacology, Faculty of Pharmacy, University of Khartoum, Khartoum, SDN 3. Zoology, Faculty of Science, University of Khartoum, Khartoum, SDN 4. Histopathology and Cytology, Ibn Sina University, Khartoum, SDN 5. Clinical Pharmacy, Faculty of Pharmacy, University of Gezira, Wad Medani, SDN 6. Research, Sidra Medicine, Doha, QAT  \nCorresponding author: Ahmed Salem, [binahmedye.ye.edu@gmail.com](binahmedye.ye.edu@gmail.com)  \nAbstract  \nIntroduction  \nCyclin-dependent kinase inhibitor 2A (CDKN2A) is a suppressor carcinogenic gene that is upregulated across various types of cancer including breast, liver, thyroid, and bile duct cancer due to its crucial role in cell cycle regulation and cell division. Nevertheless, it is mostly investigated at the genetic level, but it is still poorly studied on pan-cancer analysis as a biomarker and this study shows its significant potential diagnostic and prognostic characteristics. However, this study aims to investigate the role of CDKN2A as a diagnostic and prognostic biomarker across various types of cancer focusing primarily on colon adenocarcinoma (COAD) .  \nMethods  \nWe investigated CDKN2A gene expression in a pan-cancer analysis across different types of cancer to show its diagnostic potential characteristics by using various bioinformatic tools, including Tumor Immune Estimation Resource (TIMER) 2.0, Gene Expression Profiling Interactive Analysis (GEPIA), and University of Alabama at Birmingham Cancer Data Analysis Portal (UALCAN) database. TIMER was used to profile gene expression across 32 types of cancer composed of 10,000 RNA-seq samples obtained from the Cancer Genome Atlas (TCGA) and to analyze the tumor-infiltrating immune cells. In addition, GEPIA and UALCAN were further used to analyze gene expression, in terms of gene regulation, pathological stages, and clinical parameters, including gender, age, and race. Therefore, we used GEPIA, UALCAN, and Kaplan-Meier plotter particularly across adenocarcinoma to investigate CDKN2A prognosis by studying its high expression association with the patient’s overall survival rate to show the tumor progression. Then, we looked into the genetic alteration of CDKN2A by using the cBio Cancer Genomics Portal (cBioPortal), including 10 pancancer studies. We concluded the analysis with gene validation by using a public cohort in Gene Expression Omnibus (GEO) .  \nResults  \nCDKN2A showed a trend of upregulation in most cancers and it was significantly upregulated in five cancers, which were commonly identifiable in three databases, including breast invasive carcinoma (p \u003C 0.001), kidney chromophobe (p \u003C 0 .001), kidney renal clear cell carcinoma (p \u003C 0 .001), kidney renal papillary cell carcinoma (p \u003C 0 .001), and COAD (p \u003C 0 .001) . The upregulation was significantly different in association with pathogenic stages II and III (pr(>F) = 0 .00234) which was identifiable significantly in COAD more than in other cancers. The gene showed a high upregulation in association with poor prognosis of patient survival in three cancers, including COAD (log-rank p = 0 .011), mesothelioma (log-rank p = 5 .9e−07), and liver hepatocellular carcinoma (log-rank p = 0 .0045) . Therefore","cbCaimOvNL4HAVNV","https://ap.wps.com/l/cbCaimOvNL4HAVNV","pdf",1755972,15,"English","# Abstract\n# Introduction\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What is the main goal of the study regarding CDKN2A?\",\"answer\":\"To assess whether CDKN2A can function as a diagnostic and prognostic biomarker across multiple cancer types, with primary focus on colon adenocarcinoma (COAD).\"},{\"question\":\"Which datasets and bioinformatic tools were used for expression and immune analysis?\",\"answer\":\"TIMER 2.0, GEPIA, and UALCAN were used for gene expression profiling, while TIMER 2.0 also supports tumor-infiltrating immune cell analysis based on TCGA RNA-seq samples.\"},{\"question\":\"What key findings support CDKN2A’s biomarker potential in COAD?\",\"answer\":\"CDKN2A shows significant upregulation in COAD, stage-associated differences, and an association with poor survival, along with links between higher expression and immune cell infiltration (e.g., CD4+ T cells, macrophages, neutrophils).\"},{\"question\":\"How were genetic alterations and validation performed?\",\"answer\":\"Genetic alteration patterns were analyzed using the cBioPortal across multiple pancancer studies, and results were concluded with validation using a public cohort from Gene Expression Omnibus (GEO).\"}]","A Comprehensive Pan-Cancer Analysis Reveals Cyclin-Dependent Kinase Inhibitor 2A Gene as a Potential Diagnostic and Prognostic Biomarker in Colon Adenocarcinoma | PDF",1790041574,38,[152,156,160,164],{"page_no":8,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3f450d59cb792c8a51f2eb93c0430df.webp",983,1390,{"page_no":14,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/532aa9825e31b53ed3d5393058d3149a.webp",982,1389,{"page_no":81,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9608982ff70283ec741fca0a532d2572.webp",981,1387,{"page_no":19,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f5f31a4ee18c3034bb1a1a79d85b737.webp",980,1386]